Trusted by U.S. Physicians and Pharmacies and Available Nationwide. Take Control of Your Weight Loss Journey: How Does GLP-1 ...

A new request by Ozempic manufacturer Novo Nordisk could limit the availability of a type of GLP-1—semaglutides—to local ...

Topline data were announced from a phase 3 trial evaluating CagriSema in overweight or obese patients without type 2 diabetes.

The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with obesity.

PRNewswire/ -- (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today ...

With nutritional, pharmaceutical, and surgical options available for obesity, clinicians are being called upon to make ...

As GLP-1 RA use soars, experts are worried that patients may not be getting the right nutrients in their diets. How can ...

The best semaglutide dose for weight loss varies according to your starting weight, risks, and stage of treatment. Read to ...

Hangzhou Sciwind Biosciences Co., a pre-commercial biopharmaceutical company focusing on developing innovative therapies to treat metabolic diseases, today announced a licensing and collaboration ...